|
Jun 21
|
How to Find Strong Buy Medical Stocks Using the Zacks Rank
|
|
May 15
|
Veracyte to Participate in Upcoming Investor Conferences
|
|
May 13
|
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade
|
|
May 9
|
Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?
|
|
May 8
|
Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
|
|
May 8
|
Q1 2024 Veracyte Inc Earnings Call
|
|
May 8
|
Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ...
|
|
May 7
|
Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test Performance
|
|
May 7
|
Veracyte Announces First Quarter 2024 Financial Results
|
|
May 6
|
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
|
|
Apr 22
|
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
|
|
Apr 22
|
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
|
|
Apr 16
|
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
|
|
Apr 2
|
What Makes Veracyte (VCYT) a Lucrative Investment?
|
|
Dec 12
|
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 1
|
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
|
|
Nov 29
|
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
|
|
Nov 8
|
Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Veracyte Announces Third Quarter 2023 Financial Results
|